Signal Transduction and Targeted Therapy for Tumors

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cell Signaling".

Deadline for manuscript submissions: 28 February 2026 | Viewed by 1439

Special Issue Editor


E-Mail Website
Guest Editor
Department of Pharmacology, Moores Cancer Center, School of Medicine, University of California San Diego, La Jolla, San Diego, CA 92093, USA
Interests: molecular cell biology; cell signaling; cancer biology; cell migration; tumor biology; metastasis; pharmacology; cancer cell biology; cancer immunology; cell culture

Special Issue Information

Dear Colleagues,

Cancer represents a global health concern, with its contribution to worldwide mortality increasing each year. Due to its variety and multifactorial nature, cancer represents a complex challenge in biomedical research. Cancer therapeutics involve not only targeting tumor cells but also disrupting the communication between cancer cells and non-transformed cells that are hijacked during tumor progression, such as leukocytes (immunotherapy) or endothelial cells (anti-angiogenic therapy), thereby altering the tumor microenvironment, increasing the anti-tumor response, and reducing the dissemination of tumor cells. Analyzing the signal transduction pathways involved in angiogenic, immunosuppressive, and neurogenic switches triggered by the interaction between tumor cells and adjacent tissue cells may reveal novel therapeutic opportunities to halt and reverse tumor progression.

This Special Issue will investigate the wide range of signal transduction processes linked to cancer and explore the effectiveness of emerging therapeutic targets, drugs, and treatment combinations against cancer-associated processes, such as metastasis, migration and invasion, resistance or persistence, tumor angiogenesis, immunosuppression, tumor neurogenesis/axonogenesis, perineural invasion, and neuropathic pain. By investigating signal transduction processes linked to cancer, we may be able to develop creative targeted therapies to counteract cancer progression.

This Special Issue will showcase reviews and original research articles using cells and animal models.

Dr. Rodolfo Daniel Cervantes-Villagrana
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer progression
  • metastasis
  • invasion
  • cancer signaling
  • cell communication
  • cancer neuroscience
  • tumor angiogenesis
  • target therapy
  • immunotherapy
  • drug resistance
  • anti-tumor therapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

43 pages, 8626 KB  
Review
Advances in Targeting Growth Factor Signalling in Neuroblastoma and Overcoming Drug Resistance
by Karina Ivanenko, Ruslan Shaymardanov, Vladimir Prassolov and Timofey Lebedev
Cells 2026, 15(1), 4; https://doi.org/10.3390/cells15010004 - 19 Dec 2025
Abstract
Neuroblastoma is an embryonal tumour that arises from the malignant transformation of neural crest cells and remains one of the deadliest malignancies in children under five. Neural crest development is regulated by dynamic switches in transcriptional programmes, guided by a variety of growth [...] Read more.
Neuroblastoma is an embryonal tumour that arises from the malignant transformation of neural crest cells and remains one of the deadliest malignancies in children under five. Neural crest development is regulated by dynamic switches in transcriptional programmes, guided by a variety of growth factors. Due to its developmental origin, neuroblastoma is unique in that these tumours often retain overactivation of growth factor signalling, which can be targeted by receptor tyrosine kinase (RTK) inhibitors. However, mutations in kinases, except for ALK, are extremely rare in neuroblastoma. Furthermore, the high degree of intratumoural heterogeneity often renders RTK inhibition ineffective as a monotherapy. For high-risk tumours, which lack effective treatment options, there remains an unmet need for targeted therapies. This review summarises the roles of growth factor receptors in neural crest and neuroblastoma development in light of recent single-cell studies. We provide a systematic overview of RTK inhibitors that can target growth factor signalling in neuroblastoma and detail their current status in clinical development. We also explore the role of intratumoural heterogeneity in resistance to RTK inhibitors, focusing on the adrenergic-to-mesenchymal transition, which drives a switch in growth factor receptor expression. Finally, we discuss strategies to overcome RTK inhibitor resistance by targeting neuroblastoma cell plasticity, disrupting downstream signalling pathways, or inhibiting escape mechanisms from cell death. This review provides a theoretical basis for developing novel combination therapies incorporating RTK inhibitors. Full article
(This article belongs to the Special Issue Signal Transduction and Targeted Therapy for Tumors)
Show Figures

Figure 1

Back to TopTop